Cytosorbents (CTSO) Profit After Tax (2010 - 2026)

Cytosorbents (CTSO) has reported Profit After Tax for 17 consecutive years, with -$4.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Profit After Tax fell 326.86% year-over-year to -$4.4 million; the trailing twelve-month figure through Jun 2026 stood at -$18.2 million (down 84.58% YoY), and the FY2025 full-year result was -$8.2 million, up 60.43% from the prior year.
• Profit After Tax advanced to -$4.4 million in Q2 2026 per CTSO's latest filing, from -$5.1 million in the prior quarter.
• Across five years, Profit After Tax topped out at $1.9 million in Q2 2025 and bottomed at -$12.2 million in Q3 2022.
• Historically, Profit After Tax has averaged -$5.6 million across 5 years, with a median of -$5.8 million in 2024.
• The sharpest annual moves came in 2023 and 2025: Profit After Tax slumped 758.12% in 2023, then surged 145.34% in 2025.
• Over 5 years, Profit After Tax stood at -$766126.0 in 2022, then plunged by 758.12% to -$6.6 million in 2023, then decreased by 15.1% to -$7.6 million in 2024, then grew by 27.36% to -$5.5 million in 2025, then climbed by 19.65% to -$4.4 million in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered -$4.4 million, -$5.1 million, and -$5.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.